Tech and Biotech Destined to Merge


Technology has been pushing the envelope further and further over the past fifty years.  The rate of evolution within the technology space is not dissimilar to manufacturing during the industrial revolution.  To classify this point in time as the “Golden Age of Technology” is not a stretch.

A parallel can be drawn with the rate of evolution as it pertains towards healthcare, more specifically treatments for diseases and various ailments.  The progression of this research can be directly attributed to the advancement of technology.  Treatments and specific molecule pairings are able to be tested on a computer for viability and structural stability before beginning rounds of testing on living objects.  The advancement of the biotechnology industry mirrors the advancement of technology.

The Most Comprehensive Apple iPhone 6 Leaks and Rumors From Around the Web

With both industries developing and evolving at such a rapid pace and trajectory together, it doesn’t take a giant leap to come to our conclusion.  The technology sector and biotechnology sectors are on a collision course.  This collision course will not only benefit these two sectors, but consumers, physicians, and patients alike.

Consider Pfizer (PFE) if you will.  Pfizer is one of the largest companies in the drug space.  Pfizer has implemented the strategy of taking over smaller biotech companies to continually reprise and fill their own pipeline of innovative drugs, treatments, and the patents that go with them for years.

Then consider a company such as NXP Semiconductor (NXPI).  NXP develops and produces technology that allows consumers and businesses to complete payment transactions directly through mobile technology.  NXP has an impressive client list that includes technology giants Microsoft (MSFT), Google (GOOG), Samsung, and Apple (AAPL).  This technology is still considered to be developing, but many experts believe this will be the future of payment processing in retailers across the country.

Twitter’s Future

Let us introduce a patient into the formula.  An individual with an irregular heartbeat is able to have a pacemaker put in to stabilize the heart, increasing the overall health of the patient.  In today’s day and age, physicians are able to ascertain the functionality and health of that patient through serial numbers and a computer.  Likewise, patients are able to check the stability of the pacemaker online to ensure they don’t need to seek treatment.  Both the patient and physician are able to obtain this information without a costly invasive procedure and lengthy recovery process.

The marriage between technology and biotechnology has already begun; as we just illustrated.  However, smaller technology companies would provide giants such as Merk (MRK) and Pfizer with phenomenal growth opportunities.  With technology growing smaller and smaller reaching nano tech levels these biotech giants would benefit greatly from consuming these companies.

Using nanotech biotechnology companies could possibly watch the effectiveness of cancer treatments live, greatly increasing the understanding of the effectiveness of different treatments.  Perhaps a heart valve could use a similar nanotechnology to track the overall health of the valve, as well as the health of the heart itself.  This would be a breakthrough in treatment, patient care, and increase the efficacy of treatments and diagnoses going forward.

David Einhorn is Wrong About A Tech Bubble

Similarly, tech giants with social aspects would benefit greatly from swallowing smaller biotech firms.  Companies like Apple (AAPL), Google (GOOG), and especially Facebook (FB) would be prime candidates to pursue this route while they pursue growth opportunities.  It may not seem like a natural fit at first glance, but consider the benefit for these companies.  With the massive user base these tech giants have they would either be able to assist users with preventative treatments based on their users’ activities and patterns, or they could create a mode for users who are suffering from like ailments or enduring similar treatments to engage and support each other. A company like Mannkind (MNKD) would provide a massive growth driver to a company like Apple, with their diabetes inhaler.

The inquiry that presents itself is when will these giants in their respective sectors recognize and capitalize on this opportunity.  There is very little question as to the benefits for these sectors, consumers, physicians, or patients.  The future of medical care, treatments, and patient care is at our fingertips.

Members are notified the minute we identify an opportunity in the markets. Our members are up more than 156% YTD!

Become a member for just $54.99/month! Click the PayPal link below and start receiving email alerts within 72 hours!


About these ads